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Modeling Good Research
Practices—Overview: A Report of the
ISPOR-SMDM Modeling Good Research
Practices Task Force–1
J. Jaime Caro, MDCM, FRCPC, FACP, Andrew H. Briggs, DPhil,
Uwe Siebert, MD, MPH, MSc, ScD, Karen M. Kuntz, ScD,
On Behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force
Models—mathematical frameworks that facilitate estima-
tion of the consequences of health care decisions—have
become essential tools for health technology assessment.
Evolution of the methods since the first ISPOR modeling
task force reported in 2003 has led to a new task force,
jointly convened with the Society for Medical Decision
Making, and this series of seven papers presents the up-
dated recommendations for best practices in conceptual-
izing models; implementing state–transition approaches,
discrete event simulations, or dynamic transmission
models; dealing with uncertainty; and validating and
reporting models transparently. This overview introduces
the work of the task force, provides all the recommenda-
tions, and discusses some quandaries that require further
elucidation. The audience for these papers includes those
who build models, stakeholders who utilize their results,
and, indeed, anyone concerned with the use of models
to support decision making. Key words: modeling; meth-
ods; guidelines; good practice. (Med Decis Making
2012;32:667–677)
The use of models to support scientific endeavoris ubiquitous. Models are essentially communi-
cation tools that allow the complexity of a given
system to be reduced to its essential elements. As
such, models represent a simplification of reality,
and modeling is necessarily a reductionist method-
ology. This series of papers1-6 relates to the applica-
tion of modeling techniques to the area of health
care decision making. This can include clinical deci-
sion models—designed to assist individual clini-
cians and their patients with decisions regarding
their care—but also policy decision models, de-
signed to more broadly evaluate whether particular
health care technologies should be provided within
the context of an organized health care system. These
latter types of models are characterized by the need to
explicitly include a budget constraint and necessarily
include resource consequences and health outcomes
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in a health economic evaluation framework. There-
fore, while these papers focus on modeling (drawing
broadly on general methods) and apply beyond
health economic assessment, the series touches on
many aspects pertaining to economic evaluation.
Although the use of models to inform policy deci-
sion about the use of health technologies has been
increasing,7 there remain strong concerns with their
credibility8,9—a concern that is not unique to our
field.10-12 To help allay these concerns, several guide-
lines for goodpractices inmodelinghavebeen issued.13
In 2000, the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) Task Force
on Good Research Practices in Modeling Studies was
created, and after an extensive process of consultation,
it issued its report in 2003. This report defined amodel
and its purpose, laid out the approach to evaluating
a model, and described the task force’s consensus
regarding the attributes that characterize a goodmodel,
in terms of structure, data, and validation.14
In the intervening years, the range of modeling
techniques for medical and economic decision mod-
eling has advanced substantially,15,16 as modelers in
our discipline have become acquainted with
more sophisticated modeling techniques. The rela-
tive simplicity of cohort-based models is still an
attraction for many modelers and decision makers.
Nevertheless, there are situations when the decision
problem demands taking history into account and
individual-level microsimulation methods are
required.17 Adaptation of methods borrowed from
engineering and operations researchhas led to another
way to implement individual-level simulation mod-
els, by framing the problem in terms of the states that
individuals can be in and the events that can happen
and their consequences.18,19 These individual-level
and stochastic techniques present additional chal-
lenges and require somewhat different approaches to
modeling. Infectious disease modeling is a further
approach that canhandle interaction between individ-
uals, and this dynamic form of modeling has devel-
oped its own set of challenges and techniques.20 The
methods for simultaneouslyhandlingmultipleparam-
eters of a model and addressing uncertainty have also
progressed significantly, and the approach to valida-
tion of models has received increasing attention.
To ensure that the guidelines for good practices in
modeling remain current, effective, and helpful, ISPOR
judged it necessary to update them to accord with the
newer methods being used in practice. As a result,
a newGood Research Practices inModeling Task Force
was constituted to build on the excellent work done by
the initial one in 2000–2003. To bring to bear the broad-
est expertise in this area, the Society for Medical
DecisionMaking (SMDM)was invited to join the effort,
resulting in a joint working group tasked with provid-
ing guidelines for designing the approach, selecting
a technique, implementing and validating the model,
parameterizing the inputs and assessing uncertainty,
and using the resulting tool to inform decisionmaking.
Early in 2010, the cochairs and members of the
task force were appointed with consent from the
ISPOR and SMDM boards. The task force assembled
expert developers and experienced users of models
from academia, industry, and government, with repre-
sentation from many countries. Given the breadth of
the field at this point, a decision was made to divide
the topic into 6 components, and leads were appointed
for each. Three of these topics covered the aspects felt
to begeneral to allmodels inour field: conceptualization
of a model, estimation of model parameters and han-
dling of uncertainty, and validation of models and con-
cerns for transparency. The other 3 dealt with specific
techniques in common use: state–transition modeling,
discrete event simulation (DES), and dynamic transmis-
sion models. While there are undoubtedly topics of
interest that do not fit into these 6 papers, it was felt
that thesewouldcover themajorareasandwereatastage
of development appropriate for issuing guidelines.
The task force held its first meeting via teleconfer-
ence on May 7, 2010, and hosted information sessions
during 2010 at the ISPOR 15th Annual International
Meeting, in Atlanta, Georgia; at the 32ndAnnualMeet-
ing of the Society for Medical DecisionMaking, in Tor-
onto, Ontario; and at the ISPOR 13th Annual European
Congress, in Prague. Over numerous teleconferences
and occasional in-personmeetings, theworking groups
produced draft reports for each section. Although the
groups referred to the literature frequently, there was
no systematic attempt to review it. Though substanti-
ated as much as possible, the recommendations that
emerged represent the opinions of the experts in the
task force. These were not forced to consensus, and
had substantial differences of opinion remained, they
would have been documented as such. The draft rec-
ommendations were discussed by the task force as
a whole in a meeting held in Boston in March 2011
andsubsequently edited andcirculated to the task force
members in the form of a survey,where eachwas asked
to agree or disagree with a recommendation, and, if the
latter, to provide the reason (or reasons). Each group
received the results of the survey and endeavored to
address all rejections. In the end, therewere no dissent-
ingpositions. The final drafts of the reportswereposted
on the ISPOR and SMDMwebsites for comment by the
general membership of the societies.
A second group of experts—again, with broad rep-
resentation of modelers and users of models—was
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commissioned to formally review the papers. The
comments received were addressed by each working
group, and revised drafts of each paper were circu-
lated to the task force as a whole. After receiving
any additional comments and considering any fur-
ther revisions, the final version of eachpaperwas pre-
pared. (A copy of the original draft of this paper, as
well as the reviewer comments and author responses,
is available at the ISPOR website: http://www.ispor
.org/workpaper/Modeling-Good-Research-Practices-
Overview.asp.) A summary of these papers was pre-
sented at a plenary session of the ISPOR 16th Annual
International Meeting, in Baltimore, Maryland, in
May 2011 and again at the 33rd Annual Meeting of
the Society for Medical Decision Making in Chicago,
Illinois, in October 2011. The final versions of the
papers were then submitted simultaneously to Value
in Health and Medical Decision Making.
The audience for this set of papers encompasses
both the researchers who develop models and those
who use models to inform decisions. Investigators
charged with reviewing others’ models should find
the guidelines helpful in their assessments. Even
those affected by the decisions informed by models
and those who report on the results of modeling anal-
yses should find these recommendations useful.
It is important to note, however, that these papers are
not intended as primers on their subjects—they are not
step-by-step ‘‘how-to’’ manuals. General textbooks and
tutorial articles covering these techniques already
exist,21-25 and references to specific publications that
do address the methods are provided throughout. By
the same token, these papers are not methodological
treatises that address every aspect of a particular topic.
Instead, they propose a set of best practices for model-
ing. They focus on the types of models and approaches
taken today, not on nascent ones nor even on those
whose use is currently being debated (e.g., model aver-
aging26). Rather, we have taken the view that these
guidelines should reflect current best practice and that
expected further development of the methods will
require that these guidelines be updated in due course.
Although itmaynot be possible to follow the entire
set of recommendations in every modeling exercise,
these do represent what the task force felt to be the
best practices for modeling today, and each recom-
mendation should be given serious consideration.
Nevertheless, the guidelines are not intended for
use as a checklist to be followed unthinkingly. We
encourage modelers who believe that they should
not or cannot follow a particular recommendation
to document this divergence, its rationale and likely
consequences for their model, its results, and the
inferences that will guide decision makers.
This overview paper presents the process and
methods of the task force and gives an orientation to
the contents of each detailed paper. It also provides
all the recommendations of the task force but
without their detailed rationales and caveats. General
quandaries and gaps in knowledge not covered in the
other papers are addressed in the final section, along
with some thoughts on developments in this area.
ORIENTATION TO THE SERIES
The papers generally follow the same structure.
After an introduction, the key concepts and definitions
pertinent to each topic are laid out, followed by presen-
tationof the recommendations and their rationale. Each
group was given leeway, however, to approach their
subject in the way they felt was best. A reader wishing
to have a comprehensive view of the recommendations
should approach the papers in order: first the one deal-
ing with conceptualizing a model,1 then the three
addressing specific techniques,2–4 followed by the
paper on parameter estimation and uncertainty,5 and
concluding with the one on transparency and valida-
tion.6 If the detailed explanations are not required,
then this overview paper can be consulted for the list
of recommendations.
The conceptualization paper1 begins by defining the
termmodel. In the sense used by the task force, a model
is a mathematical framework representing some aspects
of reality at a sufficient level of detail to inform a clinical
orpolicydecision.Thepaper thenoutlines themodeling
process, which begins with carefully examining the
decision problem and laying out the elements required.
Along the way, the designers make many decisions.
They select what aspects of reality to include and the
extent to which they are detailed, driven by who their
audience is (the ‘‘perspective’’) and the imperative to
sufficiently reflect reality. They choose the time span
that themodel is to cover (‘‘timehorizon’’), its targetpop-
ulation (or populations), which interventions to con-
sider, how to structure the model, which outcomes to
report, and many other features. The paper underscores
that conceptualizing the model should precede exami-
nation of the available data to avoid designing a model
that lacks key components and thus poorly represents
the decisionproblem. It also emphasizes the importance
of understanding the policy context and broad consulta-
tion with experts. This paper concludes with guidance
on choosing a technique for implementing the model.
The three papers on modeling techniques begin with
definition of the technique and details of the key ele-
ments that characterize it.2–4 Indications on when to
use the techniqueare given, and structuringof themodel
MODELING GOOD RESEARCH PRACTICES—OVERVIEW
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using that technique is described. All three conclude
with suggestions on how to communicate that type of
model. The state–transition paper also deals briefly
with decision trees, a simpler technique that is some-
times adequate for the decision problem at hand.2 The
paper on DES spends somewhat more effort orienting
readers to the technique, given that today it is less com-
monlyused inmedical contexts.3Thepaper ondynamic
transition models devotes more space to the parameters
involvedbecause theseareacrucial andprominent com-
ponent of this type of model.4
The paper regarding parameter estimation and
uncertainty discusses each topic first and then pro-
vides the recommendation that emerges.5 Significant
effort ismade to bring order to the unruly terminology
pertaining to uncertainty (though, undoubtedly,
practitioners will still want to cling to their favorite
terms). The connection between estimation and sub-
sequent uncertainty analyses is emphasized, and the
choices of distributions are described. Calibration
methods and structural uncertainty are briefly
addressed, and the paper concludes with extensive
guidance on the reporting of uncertainty.
The final paper in the series—also giving recom-
mendations after each topic—deals with the twin
aspects of transparency and validation.6 It begins
with the thorny topic of trusting the results of amodel
enough to allow them to guide a decision and how
this can be achieved. It discusses both technical and
nontechnical documentation of a model, designed
to achieve the required transparency, emphasizing
that it is inappropriate to require that a model be
understandable at full depth by someone without
the necessary technical know-how. The types of val-
idation, their necessity and sufficiency, and interpre-
tation are then addressed in detail.
BEST PRACTICES
II. Conceptualizing the Model
II-1 Themodeling team should consult widely with sub-
ject experts and stakeholders to ensure that the model
represents disease processes appropriately and ade-
quately addresses the decision problem.
II-2 A clear written statement of the decision problem,
modeling objective, and scope of the model should be
developed. This should include the spectrum of disease
considered, perspective of the analysis, target popula-
tion, alternative interventions, health and other out-
comes, and time horizon.
II-2a The scope and structure of the model should be
consistent with, and adequate to address, the deci-
sion problem/objective and the policy context.
II-2b The perspective of the analysis should be stated
and defined. Outcomes modeled in the analysis
should be consistent with the stated perspective.
Analyses that take a perspective narrower than the
societal perspective should report which outcomes
are included and which are excluded.
II-2c The target population should be defined in terms
of geography, patient characteristics (including
comorbid conditions), and disease stage, each of
which should be appropriate to the decision problem.
II-2d Health outcomes modeled in the analysis—
which may be measured as events, cases of disease,
deaths, quality-adjusted life-years, disability-
adjusted life-years, or other measures important to
decision makers and stakeholders—should be
directly relevant to the question being asked.
II-2e Interventions or strategies modeled in the analy-
sis should be clearly defined in terms of frequency,
component services (including services that may
have preceded the intervention and that would affect
its course), dose or intensity, duration, and any varia-
tions required for target subgroups.
II-3 Although data are an essential component of
a model, the conceptual structure of a model should be
driven by the decision problem or research question
and not determined by data availability.
II-3a The choice of strategies/comparators crucially
affects results and should be determined by the deci-
sion problem and not by data availability or quality.
All feasible and practical strategies should be consid-
ered. Constraining the range of strategies should be
justified.
II-3b The time horizon of the model should be long
enough to capture relevant differences in outcomes
across strategies. A lifetime horizon may be required.
II-4 The conceptual representation of the decision prob-
lem should be used to identify key uncertainties in
model structurewhere sensitivity analyses could inform
the impact of structural choices. For example, where
a lifetime horizon is used, the impact of alternative
methods of extrapolating beyond the observed data
should be explored.
II-5 The policy context of the model should be clearly
stated. This includes who funded themodel, who devel-
oped the model, whether the model was developed for
a single application or multiple potential application,
and who the policy audience for the modeling work is.
II-6 An explicit process (expert consultations, influence
diagrams, concept mapping, or similar method) should
be used to convert the conceptualization of the problem
into an appropriate model structure to ensure that the
model reflects current theory of disease or the process
being modeled.
II-7 There are often several types of models that are suit-
able for the decision problem, and versions of each of the
three modeling types in the series can be used for the
ISPOR-SMDM TASK FORCE
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same decision problem. Some problems are more natu-
rally represented in certain modeling types than in
others.
II-7a For relatively simple models or decision prob-
lems with special characteristics (e.g., very short
time horizons, complex value structures), a decision
tree may be appropriate.
II-7b If the conceptualization involves representing
the disease or treatment process as a series of health
states, state–transition models are often appropriate,
as they may be simple to develop, debug, communi-
cate, analyze, and readily accommodate the evaluation
of parameter uncertainty. Their primary disadvantage,
the Markovian assumption that transition probabili-
ties do not depend on past history, can be addressed
by increasing the number of states. Individual-based
state–transition models (termed microsimulations),
which do not require this assumption, are an alterna-
tive when the number of states grows too large.
II-7c When the disease or treatment process includes
interactions between individuals, the modeling
methods should be able to represent and evaluate
the effects of those interactions (dynamic transmis-
sion models, DESs, agent-based models).
II-7d When the decision problem involves resource
constraints, the modeling method should be able to
represent and evaluate the effects of those constraints
(DES, agent-based models).
II-7e For some decision problems, combinations of
model types, hybrid models, and other modeling
methodologies are appropriate.
II-8 Model simplicity is desirable for transparency, ease
of validation, and description. However, the model
should be sufficiently complex to answer the question
at a level of detail consistent with the problem being
modeled and to preserve face validity to clinical
experts. Greater complexity may be necessary in policy
models that are intended to be used for many decision
problems.
III. State–Transition Models
III-1 If the decision problem can be represented with
a manageable number of health states that incorporate
all characteristics relevant to the decision problem,
including the relevant history, a cohort simulation
should be chosen because of its transparency, efficiency,
ease of debugging, and ability to conduct specific value
of information analyses. If, however, a valid representa-
tion of any aspect of the decision problemwould lead to
an unmanageable number of states, then an individual-
level state–transition model is recommended. Validity
should not be sacrificed for simplicity.
III-2 The strategies being evaluated should be clearly
defined. In particular, sequential decisions should not
be modeled within the Markov cycle tree but rather be
part of the specification of the alternative intervention
strategies that precede the Markov tree.
III-3 The starting cohort should be defined by the demo-
graphic and clinical characteristics that affect the transition
probabilities or state values (e.g., quality of life and cost).
III-4 Specification of states and transitions should gener-
ally reflect the biological/theoretical understanding of
the disease or condition being modeled.
III-5 States should adequately capture the type of inter-
vention (i.e., prevention, screening, diagnostics, treat-
ment) as well as the intervention’s benefits and harms.
III-6 States need to be homogeneous with respect to both
the observed and unobserved (i.e., not known by the
decision maker) characteristics that affect transition
probabilities.
III-7 The time horizon for the model should be suffi-
ciently large to capture all health effects and costs rele-
vant to the decision problem.
III-8 Cycle length should be short enough to represent
the frequency of clinical events and interventions.
III-9 Components of state–transition models that reflect
similar clinical courses should not be re-created but
rather should be incorporated once and linked to that
structure throughout the model.
III-10 Transition probabilities and intervention effects
should be derived from the most representative data
sources for the decision problem.
III-11 All methods and assumptions used to derive tran-
sition probabilities and intervention effects should be
described.
III-12 Parameters relating to the effectiveness of inter-
ventions derived from observational studies should be
correctly controlled for confounding. Time-varying con-
founding is of particular concern in estimating interven-
tion effects.
III-13 The valuation of intermediate outcomes/states
should be justified.
III-14 A half-cycle correction factor should be applied to
costs and effectiveness and should be applied in the first
cycle. A half-cycle correction should also be applied in
the final cycle for analyses that do not use a lifetime
horizon.
III-15 For certain decision problems, it may be important
to report not only the expected value but also the distri-
bution of the outcomes of interest.
III-16 The number of individuals modeled in an
individual-based simulation should be large enough to
generate stable estimates of the expected value of interest.
III-17 The report should use nontechnical language and
clear figures and tables that enhance the understanding
of themodel to communicate its key structural elements,
assumptions, and parameters.
III-18 In addition to final outcomes, intermediate out-
comes that enhance the understanding and transpar-
ency of the model results should be presented.
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IV. Discrete Event Simulation
IV-1 DES models should be used when the problem
under study involves constrained or limited resources.
DES is also an attractive option in nonconstrained mod-
els when there are interactions between individuals,
populations, and/or their environment; when time to
event is best described stochastically rather than with
fixed time intervals and time dependencies are impor-
tant; when individual pathways through the model are
influenced by multiple characteristics of the entity;
and when recording individual entity experience is
desirable.
IV-2 Constrained resource models should consider
health-related outcomes and not focus solely on meas-
ures of throughput.
IV-3 The effects of constrained resources should bemod-
eled if
 evaluated technologies result in differing levels of
access (e.g., different referral rates), and
 time to access referred events can have significant
effects on costs and/or outcomes (e.g., surgery).
IV-4 If downstream decisions can have significant
effects on the differences in costs and/or outcomes of
the primary object of an evaluation, the model should
be structured to facilitate analyses of alternative down-
stream decisions.
IV-5 Where there are competing risks of events, parame-
terization approaches that represent correlation
between the likelihood of competing events are pre-
ferred to the specification of separate time to event
curves for each event.
IV-6 Where possible, progression of continuous disease
parameters and the likelihood of related events should
be defined jointly to maintain the discrete event nature
of DES—for example, sample the level of the continuous
measure (e.g., A1C score) at which an event occurs and
then sample the time at which the level is reached.
IV-7 To simplify debugging and updating, submodels
should be used to structure the model. When comparing
two or more strategies within the same system (e.g., for
the same condition in a health technology assessment
model), submodels common to all strategies (e.g., pro-
gression following disease recurrence) should be
defined once and called from each strategy (i.e., all
patients experiencing a recurrence pass through the
common disease recurrence module).
IV-8 For structural sensitivity analyses, alternative
structures should be implemented within a single DES.
IV-9 Analysts should ensure that the mechanism for
applying ongoing risk (or risks) over multiple events
remains active over the relevant time horizon.
IV-10Model implementation should account for the out-
puts required for the validation and the final analyses of
themodel.Where individual-level data are required, rel-
evant outputs should be stored as attributes; otherwise,
aggregated values should be collected from each model
run to reduce the simulation burden.
IV-11 The choice between using general programming or
dedicated DES (‘‘off the shelf’’) software should be
informed by the relative importance of flexibility and
execution speed (general programming languages) ver-
susmodeling efficiency, automated structure, and trans-
parency (dedicatedDES software). Spreadsheet software
is generally inappropriate for implementing DES and
should not be used without justification.
IV-12 When run times for probabilistic sensitivity anal-
ysis are constrained, the optimal combination of run
size (per input parameter set) and numbers of alternative
input parameter sets tested should be estimated empiri-
cally to optimize the precision of the outputs of interest.
IV-13 If thenumberof strategies to compare is largeor there
are many structural assumptions to test, then ‘‘factorial
design’’ and optimumseeking approaches should beused.
IV-14 When computing time precludes adequate
representation of uncertainty, metamodeling should be
used (i.e., statistical representation of the model
input–output relationship).
IV-15 If the system to bemodeled is not empty at the start
of the time horizon to be evaluated, a warm-up period
should be used to build the system up to the starting
point if
 it can be reasonably assumed that the key parameters
have remained constant over time or
 the history of the key parameters can be incorporated
into thewarm-up period (e.g., the introduction of new
health technologies can be described).
IV-16 Animated representation of DES that displays the
experience of events by individuals is recommended as
a means of engaging with users, as well to helping to
debug the model through the identification of illogical
movements.
IV-17 Both general and detailed representations of a DES
model’s structure and logic should be reported to cover
the needs of alternative users of the model. Detailed
event documentation figures are also of benefit to the
analyst, as a point of referral when returning to a model
after a period of absence.
V. Dynamic Transmission Models
V-1 A dynamic model is needed when a modeler is try-
ing to evaluate an intervention against an infectious dis-
ease that 1) has an impact on disease transmission in the
population of interest and/or 2) alters the frequency dis-
tribution of strains (e.g., genotypes or serotypes).
V-2 The appropriate type of dynamic transmission
model should be used for the analysis in question, based
ISPOR-SMDM TASK FORCE
672  MEDICAL DECISION MAKING/SEP–OCT 2012
 at Glasgow University Library on December 20, 2012mdm.sagepub.comDownloaded from 
in part on the complexity of the interactions as well as
the size of the population of interest and the role of
chance effects. Thismodel could be deterministic or sto-
chastic and population or individual based. Justification
for the model structure should be given.
V-3Conduct sensitivity analysis on the timehorizon and
discount rate.
V-4 Conduct uncertainty analyses on known key struc-
tural assumptions that may have an impact on the con-
clusions, or justify the omission of such analyses.
V-5 When conducting sensitivity analyses, consider-
ation of important epidemic thresholds is helpful
when there is a possibility of the model exhibiting alter-
nate behaviors.
V-6 For differential equation-based models, adaptive
time step methods for numerical integration, which
allow the degree of error tolerance to be specified in
advance, are preferred to those that use a fixed time
step of indeterminate accuracy.
V-7 If using a differential equations model, provide the
model equations. Tabulate all initial values and param-
eters, including the mixing matrix and supply details of
the type of mixing considered.
V-8 If using an agent-based model, thoroughly describe
the rules governing the agents, the input parameter val-
ues, initial conditions, and all submodels.
V-9 Show the transmission dynamics over time (e.g.,
incidence and prevalence of infection and disease).
When applicable, report changes in other infection-
specific outcomes, such as strain replacement and the
emergence of resistance to antimicrobial drugs.
VI. Parameter Estimation and Uncertainty
VI-1 The systematic examination and reporting of uncer-
tainty are hallmarks of goodmodeling practice. Allmod-
eling studies should therefore include an assessment of
uncertainty as it pertains to the decision problem being
addressed.
VI-2 The role of the decision maker should be consid-
ered when presenting uncertainty analyses. In particu-
lar, the description of analytic perspective should
include an explicit statement regardingwhat is assumed
about the power of the decision makers to delay or
review decisions and to commission or mandate further
research.
VI-3 Terminology to describe concepts relating to
parameter estimation and representation of uncertainty
varies within the medical decision–modeling field and
in comparison to related fields. Authors should be aware
of this and seek to carefully define their use of terminol-
ogy to avoid potential confusion.
VI-4 All decisionmodels will have parameters that need
to be estimated. In populating models with parameter
estimates, analysts should conform to the broad princi-
ples of evidence-based medicine. For example, analysts
should 1) seek to identify and incorporate all relevant
evidence, rather than cherry-pick the best single source
of evidence for that parameter; 2) use best-practicemeth-
ods to avoid potential biases in parameter estimates that
might arise (e.g., when estimating treatment effective-
ness from observational sources); and 3) employ formal
evidence syntheses techniques (meta-analysis and net-
work meta-analysis) as appropriate.
VI-5 Whether employing deterministic sensitivity anal-
ysis methods (point estimate and range) or probabilistic
sensitivity analysis (parameterized distribution), the
link to the underlying evidence base should be clear.
VI-6 While completely arbitrary analyses, such as the
presentation of the effect on model outputs of varying
each input parameter by +/- 50%, can be used as a mea-
sure of sensitivity, such analyses should not be used to
represent uncertainty.
VI-7 Analysts should give consideration to using com-
monly adopted standards from statistics for point esti-
mate and interval estimation for input parameters,
such as 95%confidence intervals, or distributions based
on agreed statistical methods for a given estimation
problem. Where departures from these standards are
deemed necessary (or where no such standard exists
for a given estimation problem), these should be
justified.
VI-8When there is very little informationonaparameter,
analysts should adopt a conservative approach such that
the absence of evidence is reflected in a very broad range
of possible estimates. On no account should parameters
be excluded from a sensitivity analysis on the grounds
that ‘‘there is not enough information fromwhich to esti-
mate uncertainty.’’
VI-9 In choosing distributional forms for parameters in
a probabilistic sensitivity analysis, favor should be given
to continuous distributions that provide a realistic por-
trayal of uncertainty over the theoretical range of the
parameter of interest. Hence, careful consideration
should be given to whether distributions like the trian-
gular should have any role in a probabilistic sensitivity
analysis.
VI-10 Correlation among parameters should be consid-
ered. Jointly estimated parameters, such as those from
a regression analysis, will have direct evidence on correla-
tion, which should be reflected in the analysis. Indepen-
dently estimated parameters will have no such evidence,
but this should not necessarily lead to an assumption of
independence. Possible approaches are 1) to include a cor-
relation coefficient as a parameter to themodelwhere con-
cern exists that an unknown correlation between
parameters could be important or 2) to reparameterize
themodel so that that the uncertain parameters can be rea-
sonably assumed to be independent.
VI-11 Where uncertainties in structural assumptions
were identified in the process of conceptualizing and
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building amodel, those assumptions should be tested in
a sensitivity analysis. Consideration should be given to
opportunities to parameterize these uncertainties for
ease of testing. Where it is not possible to perform struc-
tural sensitivity analysis, it is nevertheless important
that analysts be aware of the potential for this form of
uncertainty to be at least as important as parameter
uncertainty for the decision maker. (Linked to concep-
tual modeling recommendations)
VI-12 Uncertainty analyses can be either deterministic
or probabilistic, and often it is appropriate to report
aspects of both types within a single evaluation. Tor-
nado diagrams, threshold plots, or simple statements
of threshold parameter values are all appropriate ways
of reporting results from deterministic sensitivity
analyses.
VI-13When additional assumptions or parameter values
are introduced for purposes of uncertainty analyses,
such as distributional parameters for probabilistic sensi-
tivity analyses or parameter ranges for deterministic sen-
sitivity analyses, these values should be disclosed and
justified. Technical appendices are often appropriate
for this purpose.
VI-14 When model calibration is used to derive parame-
ters, uncertainty around the calibrated values should
also be reported, and this uncertainty should be
reflected in either deterministic or probabilistic sensi-
tivity analyses, or both.
VI-15 When the purpose of a probabilistic sensitivity
analysis is to guide decisions about acquisition of infor-
mation to reduce uncertainty, results should be pre-
sented in terms of expected value of information.
VI-16 For economic studies, when a probabilistic sensi-
tivity analysis is performed without an accompanying
expected value of information analysis, options for pre-
senting results include cost-effectiveness acceptability
curves and distributions of net monetary benefit or net
health benefit. When more than two comparators are
involved, curves for each comparator should be plotted
on the same graph.
VII. Transparency and Validation
VII-1 Every model should have nontechnical documen-
tation that is freely accessible to any interested reader.
At a minimum, it should describe in nontechnical terms
the type of model and intended applications; funding
sources; structure of the model; inputs, outputs, other
components that determine the model’s function, and
their relationships; data sources; validation methods
and results; and limitations.
VII-2 Every model should have technical documenta-
tion, written in sufficient detail to enable a reader with
the necessary expertise to evaluate the model and
potentially reproduce it. The technical documentation
should be made available openly or under agreements
that protect intellectual property, at the discretion of
the modelers.
VII-3 Validation of a model should include an evalua-
tion of face validity of the structure, evidence, problem
formulation, and results of the model. A description of
the process used to evaluate face validity should be
made available on request. Evaluation of face validity
should be made by people who have expertise in the
problem area but are impartial to the results of an analy-
sis. If face validation raises questions about a model,
these issues should be discussed by the modelers in
their report of an analysis.
VII-4 Models should be subjected to rigorous verifica-
tion. The verification methods should be described in
the nontechnical documentation of the model. The per-
tinent results of verification should bemade available on
request.
VII-5 Modelers should search for previously published
modeling analyses of the same or similar problems and
discuss insights gained from similarities and differences
in results.
VII-6 Builders of models should have a formal process
for conducting external validation that includes
 Systematic identification of suitable data sources; jus-
tification of the selection; specification of whether
a data source is dependent, partially dependent, or
independent; and description of which parts of the
model are evaluated by each data source
 Simulation of each data source and comparison of
results
 Quantitativemeasures of howwell themodel’s results
match the outcomes observed in the data source
VII-7 Comparison of results should include descriptions
of
 Data source
 Setup of the simulation
 Discrepancies between the data source and simula-
tion setup, as well as implications of the
discrepancies
 Comparisons of simulation results with observed
results
 Discussion of discrepancies between simulation
results and observed results
 Sensitivity analyses
VII-8 Modelers should make available on request
a description of the external validation process and
results.
VII-9Modelers should identify parts of amodel that can-
not be validated because of lack of suitable data sources,
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and they should describe how uncertainty about those
parts is addressed.
VII-10 For multiapplication models, modelers should
describe criteria for determining when validations
should be repeated and/or expanded.
VII-11 When feasible with respect to the decision being
addressed and the availability of a future data source,
a model should be tested for its prediction of future
events. Builders of multiple-use models should seek
opportunities to conduct predictive validations as part
of their overall validation process.
QUANDARIES
Amajor choice to be made in the design of a model
is the technique that will be used to structure and
analyze it. Many techniques and variations are avail-
able, and with sufficient effort and ingenuity, most
problems can be structured in any of the techniques.1
This does not mean that the techniques are inter-
changeable and that the choice should be made casu-
ally. With advances in computing that render
massive calculations quite feasible, it is expected
that there will be increasing use of individual-based
simulations, as the computational challenges of
simultaneously addressing stochastic uncertainty
andparameter uncertainty in probabilistic sensitivity
analysis diminish. These are less subject to limita-
tions imposed by the cohort simulation approach,
particularly with regard to patient history based on
events experienced within the model. Whether to
frame them in terms of states or events will be of
lesser concern. Indeed, there is no reason to treat
these asmutually exclusive alternatives: hybridmod-
els with some components represented as states and
others as events are readily constructed and can be
a very flexible and accurate approach with no restric-
tions in terms of how time is handled. At the same
time, overly complex models should be avoided if
a simpler one will accurately reflect all aspects of
the decision problem.
The idea that the design of a model should not be
driven by data availability—detailed in the conceptu-
alization paper1—may rankle some on the grounds
that there is not much point in designing a detailed
model that can then not be populated by existing
data. While a model lacking information on many
inputs is not very useful, the reasons for designing
first and looking at data after are that this produces
more appropriate, relevant designs and often leads
to looking for and finding data that might otherwise
have been overlooked. The choice of data and their
processing to yield suitable inputs for the model is
a vast topic covered in other fields, such as epidemi-
ology. While this series does not address this in any
detail, it is emphasized that good practice of
evidence-based medicine should be followed. What-
ever choices are made, the model parameters should
reflect the uncertainty over the data gaps,5 whichwill
ensure that a value of information analysis will pro-
vide the necessary impetus to launch studies to
obtain the necessary data.
The converse situation is also of note: that detailed
data exist is not a sufficient reason to build a very
complex model. The art of building models rests on
the principle of parsimony, or Occam’s razor. We do
not suggest that finding the balance between simplic-
ity of modeling and avoidance of oversimplification
is easy, but it is perhaps the most important skill
that a modeler can learn if a model is to truly fulfill
its potential as a communication tool. Excessive
detail and complexity reduce transparency and can
lead to distrust in models and in the modeling com-
munity among those we seek to inform.
Throughout the series of papers, the subject of
structural uncertainty keeps cropping up. This is
a particularly difficult issue.27 There is no doubt
that the choices made in structuring the model can
significantly affect the results and, thus, the inferen-
ces made from them. In many cases, those choices
are based on expert opinion or influenced by con-
cerns for simplicity, feasibility of implementation,
and so on. This process leaves much room for uncer-
tainty, but it is very difficult to quantify and analyze
this uncertainty. This hurdle is augmented by using
software not designed for modeling—many of those
that are specific for simulation include features that
facilitate structural sensitivity analysis. In principle,
all the alternatives considered could be modeled and
the impact on the results examined. The effort
involved tends to be perceived as prohibitive,
though, and even if the investment were made, the
universe of possibilities is vast and extends beyond
what the individual modeler might consider. Clearly,
structural uncertainty is a topic ripe for intensive
research. Hopefully, the next edition of the guide-
lines will be able to provide firm recommendations
in this regard.
The paper on uncertainty states that arbitrary
ranges should not be used when examining the
impact of uncertainty on the results.5 The reason is
that such an analysis reveals how sensitive themodel
is to changes in that input but it does not address
uncertainty, since the range of values is not a reflec-
tion of the latter. This poses a practical dilemma for
MODELING GOOD RESEARCH PRACTICES—OVERVIEW
ARTICLES 675
 at Glasgow University Library on December 20, 2012mdm.sagepub.comDownloaded from 
modelers: how to address uncertainty when it is clear
that an input is not exact but when it is not clear to
what degree. One could argue that the solution is to
collect data on that input and use that process to
quantify the uncertainty. This will usually not be fea-
sible in a timely way, however. Thus, an option
would be to employ Bayesian methods to create
a probability distribution around the estimate and
to use this to quantify the relevant uncertainty. Given
the practical and methodological difficulties, this
area should be a focus of research.
Often when reporting the results of a model analy-
sis, the term robust is used. This term may be misin-
terpreted to mean that the results are unaffected by
changes to the inputs, whereas it should indicate
that within the uncertainty of the inputs, the conclu-
sions (i.e., suggested decisions) were not altered. It
would be quite worrisome if a model did not react
to changes in its inputs; were this to be the case,
one would conclude that there must be a major prob-
lem with the model, as a proper one should respond
to changes in inputs. Also, this is not a property of
a model but rather of a particular analysis and set of
results. Robustness is not per se a desirable feature.
Instead, what investigators should examine are the
conditions that alter the implications for the decision
at issue and their credibility.
A particularly difficult aspect tackled by the task
force is the conflict between the scientific desirability
of making all methodological and technical details of
amodel available to other researchers and the need to
protect intellectual property generated by substantial
investments in the development of a model. As
rejecting the latter would significantly reduce the
incentive to devote major efforts to creating
models—particularly those intended for multiple
uses—the task force agreed, reluctantly, to not recom-
mend that intellectual property be ignored. Instead,
theproposal is to ask thatmodelersmake full technical
documentation available within whatever agreements
they feel are necessary to grant them adequate protec-
tion. This should allow for detailed review of any
model by other scientists, provided they are willing
to abide by the confidentiality restrictions.
A final quandary is that our field creates models to
address decisions regarding the use of limited resour-
ces but these typically assume away the actual short-
term resource constraints. Most models regularly
assume that any resource that is needed is immedi-
ately available and consumed, regardless of actual
supply (or likely demand). Thus, the vexing health
care queues common in many countries are not
incorporated, nor are changes in waiting times as
a consequence of new interventions. As a conse-
quence, the potential for helping health systems
adapt to changing health care practice in the short
term has perhaps been overlooked in comparison to
the use of modeling to estimate the long-term cost-
effectiveness of new technologies. Incorporating
this aspect would undoubtedly add another layer
of complexity to models and a further demand for
data that might be difficult to obtain, but it is a gap
in current practice. Perhaps by the time the next
guidelines are developed, our field will have
advanced to assist decision makers not only with
the challenge of which interventions to adopt but
alsowith that of handling the implementation of sys-
tem changes more efficiently.
CONCLUSION
The recommendations for best practices provided
in this paper and detailed in the accompanying six
papers are intended, in the first instance, for practi-
tioners who build models. Nevertheless, they should
be of use to the decisionmakers who are the audience
for the models’ results, as well as those who commis-
sion models, the granting agencies that fund them,
and even those who report on the results and their
implications.
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